Review article · 2024

Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer

Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, Keechilat Pavithran, Ashok R Unni, M S Sithara, Manjit Sarma, Thacho Sukumaran Mangalanandan

Molecular Pharmaceutics, 21(12), 5960–5988 · Published 19 November 2024 · DOI 10.1021/acs.molpharmaceut.4c00801

View at the publisherCite this paper

In brief

“Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer” is a 2024 review article by Sreejith Thrivikraman Nair and 7 co-authors, published in Molecular Pharmaceutics. OpenAlex counts 18 citations as of 21 November 2026, which puts it in the top 2% of works published in 2024 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
18
Most cited in
2026 (12)
Field-weighted impact
0.40
References
250
Authors
8

Abstract

Tumor heterogeneity poses a significant challenge in cancer therapy. To address this, we analyze pharmacotherapeutic challenges by categorizing them into static and dynamic barriers, reframing these challenges to improve drug delivery, efficacy, and the development of controlled-release nanomedicines (CRNMs). This pathophysiology-driven approach facilitates the design of novel therapeutics tailored to overcome obstacles in pancreatic ductal… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nair, S. T., Abhi, C., Kamalasanan, K., Pavithran, K., Unni, A. R., Sithara, M. S., Sarma, M., & Mangalanandan, T. S. (2024). Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics, 21(12), 5960–5988. https://doi.org/10.1021/acs.molpharmaceut.4c00801

MLA 9

Nair, Sreejith Thrivikraman, et al. “Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer.” Molecular Pharmaceutics, vol. 21, no. 12, 2024, pp. 5960–5988. https://doi.org/10.1021/acs.molpharmaceut.4c00801.

Chicago

Nair, Sreejith Thrivikraman, C Abhi, Kaladhar Kamalasanan, Keechilat Pavithran, Ashok R Unni, M S Sithara, Manjit Sarma, and Thacho Sukumaran Mangalanandan. 2024. “Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer.” Molecular Pharmaceutics 21 (12): 5960–5988. https://doi.org/10.1021/acs.molpharmaceut.4c00801.

Harvard

Nair, S. T. et al. (2024) ‘Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer’, Molecular Pharmaceutics, 21(12), pp. 5960–5988. doi:10.1021/acs.molpharmaceut.4c00801.

IEEE

S. T. Nair et al., “Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer,” Molecular Pharmaceutics, vol. 21, no. 12, pp. 5960–5988, 2024, doi: 10.1021/acs.molpharmaceut.4c00801.

BibTeX

@article{nair2024pathophysiology,
  title     = {{Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer}},
  author    = {Nair, Sreejith Thrivikraman and Abhi, C and Kamalasanan, Kaladhar and Pavithran, Keechilat and Unni, Ashok R and Sithara, M S and Sarma, Manjit and Mangalanandan, Thacho Sukumaran},
  journal   = {Molecular Pharmaceutics},
  year      = {2024},
  volume    = {21},
  number    = {12},
  pages     = {5960--5988},
  doi       = {10.1021/acs.molpharmaceut.4c00801},
  url       = {https://doi.org/10.1021/acs.molpharmaceut.4c00801}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • pancreatic ductal adenocarcinoma
  • tumor heterogeneity
  • drug delivery barriers
  • nanoparticle drug delivery
  • RNA interference
  • evofosfamide
  • Notch signaling
  • Hedgehog signaling

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Nair, S. T., Abhi, C., Kamalasanan, K., Pavithran, K., Unni, A. R., Sithara, M. S., Sarma, M., & Mangalanandan, T. S. (2024). Pathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer. Molecular Pharmaceutics, 21(12), 5960–5988. https://doi.org/10.1021/acs.molpharmaceut.4c00801

How many times has this paper been cited?

18 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Sreejith Thrivikraman Nair, C Abhi, Kaladhar Kamalasanan, Keechilat Pavithran, Ashok R Unni, M S Sithara, Manjit Sarma, Thacho Sukumaran Mangalanandan.

What is the DOI of this paper?

10.1021/acs.molpharmaceut.4c00801, permanently at https://doi.org/10.1021/acs.molpharmaceut.4c00801. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.